Literature DB >> 30301599

Cervical cancer cells produce TGF-β1 through the CD73-adenosine pathway and maintain CD73 expression through the autocrine activity of TGF-β1.

Rosario García-Rocha1, Alberto Monroy-García2, Jorge Hernández-Montes3, Benny Weiss-Steider3, Vianey Gutiérrez-Serrano2, María Del Carmen Fuentes-Castañeda4, Luis Roberto Ávila-Ibarra5, Christian Azucena Don-López3, Daniela Berenice Torres-Pineda6, María de Lourdes Mora-García7.   

Abstract

In cancer, the adenosinergic pathway participates in the generation of an immunosuppressive microenvironment and in the promotion of tumor growth through the generation of adenosine (Ado). The present study analyzed the participation of Ado, generated through the functional activity of the cervical cancer (CeCa) pathway in CeCa cells, to induce the expression and secretion of TGF-β1, as well as the participation of this factor to maintain CD73 expression. Ado concentrations greater than 10 μM were necessary to induce an increase of over 50% in the production and expression of TGF-β1 in CeCa tumor cells. Blockade of A2AR and A2BR with the specific antagonists, ZM241385 and MRS1754, respectively, strongly reversed the production of TGF-β1. TGF-β1 produced by CeCa cells was necessary to maintain CD73 expression because the addition of anti-TGF-β neutralizing antibodies or the inhibition of TGF-βRI strongly reversed the expression of CD73 in the CeCa cells. These results suggested a feedback loop in CeCa cells that favors immunosuppressive activity through the production of TGF-β1 and Ado as well as the autocrine activity of TGF-β1 and expression of CD73.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Adenosine; CD73; Cervical cancer; TGF-β

Mesh:

Substances:

Year:  2018        PMID: 30301599     DOI: 10.1016/j.cyto.2018.09.018

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  7 in total

Review 1.  Regulation of tumor infiltrated innate immune cells by adenosine.

Authors:  Regina Strakhova; Octavia Cadassou; Emeline Cros-Perrial; Lars Petter Jordheim
Journal:  Purinergic Signal       Date:  2020-06-12       Impact factor: 3.765

2.  Therapeutic efficacy and mechanism of CD73-TGFβ dual-blockade in a mouse model of triple-negative breast cancer.

Authors:  Yun Xing; Zhi-Qiang Ren; Rui Jin; Liang Liu; Jin-Peng Pei; Ker Yu
Journal:  Acta Pharmacol Sin       Date:  2022-01-26       Impact factor: 7.169

Review 3.  Purinergic signaling and tumor microenvironment in cervical Cancer.

Authors:  Marta Schmidt Pfaffenzeller; Maria Luiza Mukai Franciosi; Andréia Machado Cardoso
Journal:  Purinergic Signal       Date:  2020-03-13       Impact factor: 3.765

Review 4.  The adenosine pathway in immuno-oncology.

Authors:  Bertrand Allard; David Allard; Laurence Buisseret; John Stagg
Journal:  Nat Rev Clin Oncol       Date:  2020-06-08       Impact factor: 66.675

Review 5.  Cervical Cancer Immunotherapy: Facts and Hopes.

Authors:  Louise Ferrall; Ken Y Lin; Richard B S Roden; Chien-Fu Hung; T-C Wu
Journal:  Clin Cancer Res       Date:  2021-04-22       Impact factor: 12.531

6.  Detection of CD39 and a Highly Glycosylated Isoform of Soluble CD73 in the Plasma of Patients with Cervical Cancer: Correlation with Disease Progression.

Authors:  Ricardo Muñóz-Godínez; María de Lourdes Mora-García; Benny Weiss-Steider; Juan José Montesinos-Montesinos; Adriana Del Carmen Aguilar-Lemarroy; Rosario García-Rocha; Jorge Hernández-Montes; Christian Azucena Don-López; Luis Roberto Ávila-Ibarra; Daniela Berenice Torres-Pineda; Gabriela Molina-Castillo; Rommel Chacón-Salinas; Luis Vallejo-Castillo; Sonia Mayra Pérez-Tapia; Alberto Monroy-García
Journal:  Mediators Inflamm       Date:  2020-12-07       Impact factor: 4.711

7.  The Prognostic Role of CD73/A2AR Expression and Tumor Immune Response in Periampullary Carcinoma Subtypes.

Authors:  Dina Sweed; Mohammad Taha; Sara Abd Elhamed; Asmaa Shams El Dein Mohamed
Journal:  Asian Pac J Cancer Prev       Date:  2022-04-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.